Clinical, Molecular and Metabolic Characteristics of Parkinson's Disease (PD) Patients With Parkin Mutation

Parkinson's Disease Clinical Trial

Official title:

Comparison of Clinical, Molecular and Metabolic Characteristics of PD Patients With and Without Parkin Mutation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00169364
• Other study ID #: P011104
• Status: Recruiting
• Phase: N/A
• First received: September 12, 2005
• Last updated: August 28, 2007
• Start date: May 2002

Study information

• Verified date: September 2005
• Source: Groupe Hospitalier Pitie-Salpetriere
• Contact: Alexis Brice, MD, PhD
• Phone: 33-142162183
• Email: brice[@]ccr.jussieu.fr
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Parkinson's disease is a frequent neurodegenerative disorder. Genetic forms of the disease have been recently identified. The monogenic form due to parkin mutation is responsible for many familial cases and sporadic forms. However, the relationship between the mutation and the genotype of patients is not fully established. The aim of this study is to compare clinical, metabolic and neuropsychological characteristics obtained in patients with parkin mutation with those of patients without parkin mutation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Juvenile Parkinson's disease (< 45 years)

• Parkin mutation

• Normal brain magnetic resonance imaging (MRI)

Exclusion Criteria:

• Contraindication to brain MRI

• Women without effective contraception

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Device:
• positron emission tomography

Locations

Country	Name	City	State
France	Centre d'Investigation Clinique-Hôpital Pitié-Salpetriere	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Groupe Hospitalier Pitie-Salpetriere	Délégation Régionale à la Recherche Clinique

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Parkin mutation
Primary	Motor disability
Primary	Neuropsychological evaluation
Primary	Psychiatric evaluation
Secondary	Positron emission tomography